Home › Companies › ALLOGENE THERAPEUTICS INC. › 2023-2024
Compiled from SEC Form N-PX filings and ALLOGENE THERAPEUTICS INC.’s Form 8-K, filed June 10, 2024 (Item 5.07 on EDGAR). Page generated October 18, 2026.
Meeting of June 5, 2024: 6 items on ALLOGENE THERAPEUTICS INC.’s Form 8-K, filed June 10, 2024: 4 elected · 2 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore ALLOGENE THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are ALLOGENE THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: John DeYoung | 121,177,479 | -- | -- | 17,019,993 | 15,800,932 | 88% | Elected | — |
| Elect Director: Franz Humer, Ph.D. | 119,919,567 | -- | -- | 18,277,905 | 15,800,932 | 87% | Elected | — |
| Elect Director: Joshua Kazam | 127,917,055 | -- | -- | 10,280,417 | 15,800,932 | 93% | Elected | — |
| Elect Director: Stephen Mayo, Ph.D. | 130,166,905 | -- | -- | 8,030,567 | 15,800,932 | 94% | Elected | — |
| 2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers | 119,741,038 | 16,298,878 | 2,157,556 | -- | 15,800,932 | 88% | Approved | — |
| 3. Ratification of the Selection of Independent Registered Public Accounting Firm | 152,503,468 | 1,359,400 | 135,536 | -- | 0 | 99.1% | Approved | — |
Source: ALLOGENE THERAPEUTICS INC., Form 8-K, filed with the SEC on June 10, 2024 — read the filing on EDGAR.
Each item below shows how the 173 asset managers that disclosed a ALLOGENE THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Franz Humer, Ph.D.
ALLOGENE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Franz Humer, Ph.D.”): 119,919,567 for, 18,277,905 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the four persons listed below as Class III Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 63 asset managers below reported 31,417,352 for, 9,729,946 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 15,784,639 | 0 | 0 | 681,640 | For |
| Vanguard | 11,538,299 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 3,466,056 | Withhold |
| PRIMECAP Odyssey Funds | 1,926,671 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 859,326 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 829,338 | Withhold |
| State Street | 783 | 0 | 0 | 772,299 | Withhold |
| Dimensional | 0 | 0 | 0 | 598,915 | Withhold |
| JPMorgan | 591,783 | 0 | 0 | 0 | For |
| BlackRock | 515,139 | 0 | 0 | 0 | For |
| Equitable | 146,911 | 0 | 0 | 191,781 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 330,399 | Withhold |
| TIAA | 0 | 0 | 0 | 273,456 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 243,287 | Withhold |
| Global X | 194,981 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 170,481 | 0 | 0 | 0 | For |
| SEI | 159,080 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 0 | 149,496 | Withhold |
| Amplify ETF Trust | 0 | 0 | 0 | 147,277 | Withhold |
| Delaware/Macquarie | 0 | 0 | 0 | 146,779 | Withhold |
| ProShares | 0 | 0 | 0 | 140,284 | Withhold |
| American Century | 0 | 0 | 0 | 128,919 | Withhold |
| Lincoln Financial | 32,239 | 0 | 0 | 85,015 | Mixed |
| ALPS ETF Trust | 0 | 0 | 0 | 106,980 | Withhold |
| RMB INVESTORS TRUST | 0 | 0 | 0 | 101,375 | Withhold |
Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.
Combines 4 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: John DeYoung
ALLOGENE THERAPEUTICS INC.’s own tally for this item (“Elect Director: John DeYoung”): 121,177,479 for, 17,019,993 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the four persons listed below as Class III Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 63 asset managers below reported 31,480,142 for, 9,667,156 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 15,784,639 | 0 | 0 | 681,640 | For |
| Vanguard | 11,538,299 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 3,466,056 | Withhold |
| PRIMECAP Odyssey Funds | 1,926,671 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 859,326 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 829,338 | Withhold |
| State Street | 783 | 0 | 0 | 772,299 | Withhold |
| Dimensional | 0 | 0 | 0 | 598,915 | Withhold |
| JPMorgan | 591,783 | 0 | 0 | 0 | For |
| BlackRock | 515,139 | 0 | 0 | 0 | For |
| Equitable | 146,911 | 0 | 0 | 191,781 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 330,399 | Withhold |
| TIAA | 0 | 0 | 0 | 273,456 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 243,287 | Withhold |
| Global X | 194,981 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 170,481 | 0 | 0 | 0 | For |
| SEI | 159,080 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 0 | 149,496 | Withhold |
| Amplify ETF Trust | 0 | 0 | 0 | 147,277 | Withhold |
| Delaware/Macquarie | 0 | 0 | 0 | 146,779 | Withhold |
| ProShares | 0 | 0 | 0 | 140,284 | Withhold |
| American Century | 0 | 0 | 0 | 128,919 | Withhold |
| Lincoln Financial | 32,239 | 0 | 0 | 85,015 | Mixed |
| ALPS ETF Trust | 0 | 0 | 0 | 106,980 | Withhold |
| RMB INVESTORS TRUST | 0 | 0 | 0 | 101,375 | Withhold |
Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.
Combines 3 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Joshua Kazam
ALLOGENE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Joshua Kazam”): 127,917,055 for, 10,280,417 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the four persons listed below as Class III Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 63 asset managers below reported 37,097,645 for, 4,049,653 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 16,466,279 | 0 | 0 | 0 | For |
| Vanguard | 11,538,299 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,466,056 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 1,926,671 | 0 | 0 | 0 | For |
| Charles Schwab | 859,326 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 829,338 | Withhold |
| State Street | 783 | 0 | 0 | 772,299 | Withhold |
| Dimensional | 0 | 0 | 0 | 598,915 | Withhold |
| JPMorgan | 591,783 | 0 | 0 | 0 | For |
| BlackRock | 515,139 | 0 | 0 | 0 | For |
| Equitable | 185,184 | 0 | 0 | 153,508 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 330,399 | Withhold |
| TIAA | 273,456 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 243,287 | Withhold |
| Global X | 194,981 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 170,481 | 0 | 0 | 0 | For |
| SEI | 159,080 | 0 | 0 | 0 | For |
| John Hancock | 108,692 | 0 | 0 | 40,804 | Mixed |
| Amplify ETF Trust | 147,277 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 146,779 | Withhold |
| ProShares | 0 | 0 | 0 | 140,284 | Withhold |
| American Century | 0 | 0 | 0 | 128,919 | Withhold |
| Lincoln Financial | 32,239 | 0 | 0 | 85,015 | Mixed |
| ALPS ETF Trust | 0 | 0 | 0 | 106,980 | Withhold |
| RMB INVESTORS TRUST | 0 | 0 | 0 | 101,375 | Withhold |
Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.
Combines 3 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Stephen Mayo, Ph.D.
ALLOGENE THERAPEUTICS INC.’s own tally for this item (“Elect Director: Stephen Mayo, Ph.D.”): 130,166,905 for, 8,030,567 withheld, per its Form 8-K filed June 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the four persons listed below as Class III Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 63 asset managers below reported 38,159,280 for, 2,988,018 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 16,466,279 | 0 | 0 | 0 | For |
| Vanguard | 11,538,299 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,466,056 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 1,926,671 | 0 | 0 | 0 | For |
| Charles Schwab | 859,326 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 829,338 | Withhold |
| State Street | 772,033 | 0 | 0 | 1,049 | For |
| Dimensional | 0 | 0 | 0 | 598,915 | Withhold |
| JPMorgan | 591,783 | 0 | 0 | 0 | For |
| BlackRock | 515,139 | 0 | 0 | 0 | For |
| Equitable | 338,692 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 330,399 | Withhold |
| TIAA | 273,456 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 243,287 | Withhold |
| Global X | 194,981 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 170,481 | 0 | 0 | 0 | For |
| SEI | 159,080 | 0 | 0 | 0 | For |
| John Hancock | 108,692 | 0 | 0 | 40,804 | Mixed |
| Amplify ETF Trust | 147,277 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 146,779 | Withhold |
| ProShares | 0 | 0 | 0 | 140,284 | Withhold |
| American Century | 0 | 0 | 0 | 128,919 | Withhold |
| Lincoln Financial | 100,039 | 0 | 0 | 17,215 | Mixed |
| ALPS ETF Trust | 0 | 0 | 0 | 106,980 | Withhold |
| RMB INVESTORS TRUST | 0 | 0 | 0 | 101,375 | Withhold |
Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.
Combines 8 wordings of this item as funds reported it.
88% Approved · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.
ALLOGENE THERAPEUTICS INC.’s own tally for this item (“2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers”): 119,741,038 for, 16,298,878 against — passed, per its Form 8-K filed June 10, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement for the Annual Meeting.”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 16,466,279 | 0 | 0 | 0 | For |
| Vanguard | 11,538,299 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 3,466,056 | 0 | 0 | Against |
| PRIMECAP Odyssey Funds | 1,926,671 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 859,326 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 0 | 829,338 | 0 | 0 | Against |
| State Street | 772,033 | 1,049 | 0 | 0 | For |
| Dimensional | 0 | 598,915 | 0 | 0 | Against |
| JPMorgan | 591,783 | 0 | 0 | 0 | For |
| BlackRock | 515,139 | 0 | 0 | 0 | For |
| Equitable | 146,911 | 191,781 | 0 | 0 | Mixed |
| AIG/SunAmerica | 0 | 330,399 | 0 | 0 | Against |
| TIAA | 0 | 273,456 | 0 | 0 | Against |
| Goldman Sachs | 0 | 243,287 | 0 | 0 | Against |
| Global X | 194,981 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 170,481 | 0 | 0 | 0 | For |
| SEI | 159,080 | 0 | 0 | 0 | For |
| John Hancock | 0 | 149,496 | 0 | 0 | Against |
| Amplify ETF Trust | 0 | 147,277 | 0 | 0 | Against |
| Delaware/Macquarie | 0 | 146,779 | 0 | 0 | Against |
| ProShares | 0 | 140,284 | 0 | 0 | Against |
| American Century | 0 | 128,919 | 0 | 0 | Against |
| Lincoln Financial | 100,039 | 17,215 | 0 | 0 | Mixed |
| ALPS ETF Trust | 0 | 106,980 | 0 | 0 | Against |
| RMB INVESTORS TRUST | 0 | 101,375 | 0 | 0 | Against |
Fund voting reports, all 62 managers: 32,943,208 for, 8,204,090 against. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 20,001,060 | 0 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 5,567,586 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 4,263,806 | 0 | 0 | Against |
| BlackRock | 3,494,275 | 62,179 | 0 | 0 | For |
| Woodline Partners LP | 2,642,690 | 0 | 0 | 0 | For |
| JPMorgan | 2,560,911 | 1,793 | 0 | 0 | For |
| State Street | 1,910,470 | 34,496 | 0 | 0 | For |
| Wildcat Capital Management, LLC | 0 | 0 | 1,920,787 | 0 | Abstain |
| Vida Ventures Advisors, LLC | 1,798,163 | 0 | 0 | 0 | For |
| Vestal Point Capital, LP | 0 | 986,117 | 0 | 0 | Against |
| Charles Schwab | 0 | 859,326 | 0 | 0 | Against |
| Rafferty Asset Management, LLC | 0 | 829,338 | 0 | 0 | Against |
| Two Sigma | 0 | 804,245 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 801,297 | 0 | 0 | 0 | For |
| BBR PARTNERS, LLC | 798,899 | 0 | 0 | 0 | For |
| Citadel | 789,961 | 0 | 0 | 0 | For |
| NORDEA INVESTMENT MANAGEMENT AB | 0 | 742,114 | 0 | 0 | Against |
| Northern Trust | 538,730 | 47 | 0 | 0 | For |
| Cerity Partners LLC | 430,481 | 0 | 0 | 0 | For |
| Coastal Bridge Advisors, LLC | 0 | 386,045 | 0 | 0 | Against |
| Dimensional | 0 | 340,586 | 0 | 0 | Against |
| Nuveen | 0 | 275,144 | 0 | 0 | Against |
| Eaton Vance | 0 | 237,155 | 0 | 0 | Against |
| Mitsubishi UFJ Asset Management Co., Ltd. | 0 | 220,994 | 0 | 0 | Against |
| Goldman Sachs | 0 | 220,645 | 0 | 0 | Against |
Institutional-manager reports, all 125 managers: 42,151,865 for, 11,997,032 against, 1,920,787 abstained, 12,500 not voted. Showing the 25 largest; see all in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.1% Approved · of votes cast
Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.
ALLOGENE THERAPEUTICS INC.’s own tally for this item (“3. Ratification of the Selection of Independent Registered Public Accounting Firm”): 152,503,468 for, 1,359,400 against — passed, per its Form 8-K filed June 10, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending …”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 63 asset managers below reported 41,147,298 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 16,466,279 | 0 | 0 | 0 | For |
| Vanguard | 11,538,299 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,466,056 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 1,926,671 | 0 | 0 | 0 | For |
| Charles Schwab | 859,326 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 829,338 | 0 | 0 | 0 | For |
| State Street | 773,082 | 0 | 0 | 0 | For |
| Dimensional | 598,915 | 0 | 0 | 0 | For |
| JPMorgan | 591,783 | 0 | 0 | 0 | For |
| BlackRock | 515,139 | 0 | 0 | 0 | For |
| Equitable | 338,692 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 330,399 | 0 | 0 | 0 | For |
| TIAA | 273,456 | 0 | 0 | 0 | For |
| Goldman Sachs | 243,287 | 0 | 0 | 0 | For |
| Global X | 194,981 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 170,481 | 0 | 0 | 0 | For |
| SEI | 159,080 | 0 | 0 | 0 | For |
| John Hancock | 149,496 | 0 | 0 | 0 | For |
| Amplify ETF Trust | 147,277 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 146,779 | 0 | 0 | 0 | For |
| ProShares | 140,284 | 0 | 0 | 0 | For |
| American Century | 128,919 | 0 | 0 | 0 | For |
| Lincoln Financial | 117,254 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 106,980 | 0 | 0 | 0 | For |
| RMB INVESTORS TRUST | 101,375 | 0 | 0 | 0 | For |
Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 170,452,967 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 9.66% |
| 2 | Vanguard | 6.77% |
| 3 | T. Rowe Price | 2.03% |
| 4 | PRIMECAP Odyssey Funds | 1.13% |
| 5 | Charles Schwab | 0.50% |
| 6 | Direxion Shares ETF Trust | 0.49% |
| 7 | State Street | 0.45% |
| 8 | Dimensional | 0.35% |
| 9 | JPMorgan | 0.35% |
| 10 | BlackRock | 0.30% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 11.73% |
| 2 | PRIMECAP MANAGEMENT CO/CA/ | 3.27% |
| 3 | T. Rowe Price | 2.50% |
| 4 | BlackRock | 2.09% |
| 5 | Woodline Partners LP | 1.55% |
| 6 | JPMorgan | 1.50% |
| 7 | State Street | 1.14% |
| 8 | Wildcat Capital Management, LLC | 1.13% |
| 9 | Vida Ventures Advisors, LLC | 1.05% |
| 10 | Vestal Point Capital, LP | 0.58% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Fidelity Management Research LLC | 14.81% | DEF14A |
| Pfizer Inc. | 12.93% | DEF14A |
| David Bonderman | 10.98% | DEF14A |
| TPG GP A, LLC | 10.98% | DEF14A |
| BlackRock | 10.28% | 13F |
| David Chang, M.D., Ph.D. | 5.89% | DEF14A |
| Arie Belldegrun, M.D. | 5.86% | DEF14A |
| State Street | 5.39% | 13F |
| Vanguard Group | 5.29% | 13F |
| T. Rowe Price | 2.45% | 13F |
Percentages above are of 170,452,967 shares outstanding, as reported by ALLOGENE THERAPEUTICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ALLOGENE THERAPEUTICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.
At ALLOGENE THERAPEUTICS INC.'s shareholder meeting held June 5, 2024, in the 2023-2024 proxy season, 173 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 1,420 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — ALLOGENE THERAPEUTICS INC.'s filing reports the proposal as approved, with 88% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ALLOGENE THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 10, 2024.
ALLOGENE THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.